| Autor: |
Zhgun ES; Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia., Kislun YV; Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia., Kalachniuk TN; Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia., Veselovsky VA; Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia., Urban AS; Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia., Tikhonova PO; Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia., Pavlenko AV; Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia., Ilchenko GN; Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia., Ilina EN; Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia. |
| Abstrakt: |
Inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn's disease (CD), are chronic intestinal inflammatory disorders with an unknown etiology. They are characterized by chronic recurrent inflammation of the intestinal mucosa and lead to a significant decrease in the quality of life and death of patients. IBD are associated with suppression of normal intestinal microflora, including a decrease in bacteria, producers of short chain fatty acids (SCFAs), exhibiting anti-inflammatory and protective properties. Among the various methods of intestinal microflora correction, fecal microbiota transplantation (FMT), which engrafts the fecal microbiota from a healthy donor into a patient recipient, is of a particular interest. As a result, a positive therapeutic effect is observed, accompanied by the restoration of the normal intestinal microflora of the patient. A significant drawback of the method is the lack of standardization. Metabolites produced by intestinal microflora, namely SCFAs, allow objective assessment of the functional state of the intestinal microbiota and, consequently, the success of the FMT procedure. Using gas chromatography and nuclear magnetic resonance spectroscopy techniques, we have analyzed concentrations and molar ratios of SCFAs in fecal samples of 60 healthy donors. Results were in good accord when comparing two methods as well as with published data. Analysis of SCFAs in feces of patients with UC (19 patients) and CD (17 patients) revealed a general decrease in the concentration of fatty acids in the experimental groups with significant fluctuations in the values in experimental groups compared to control group of healthy donors. On the limited group of IBD patients (6 patients with UC and 5 patients with CD) concentration of SCFAs before and within 30 days of observation after FMT was determined. It was shown that FMT had a significant impact on the SCFAs levels within 1 month term; tendency to reach characteristics of healthy donors is unambiguously traced for both diseases. |
